Goldman Small Cap Research Sets A $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED) And Projects The Medical Device Company, Fo-cused On Chronic And Acute Pain Relief, Will Reach Volumes Of $1.55 Million In FY2021 And $17

Goldman Small Cap Research sets a $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED), in its Opportunity Research report released today (November 18, 2020). The investment analysis projects that the medical device company, focused on chronic and acute pain relief, will reach volumes of $1.55 Million in FY2021 and $17 Million in FY2022. Succeeding in a pain prescription market estimated at $24 billion by Mizhou Securities USA, the report estimates the large jump in FY2022 volume it projects from the success of the WellnessPlus POD, expected to be released in late 2021 after FDA clearance. Electromedical Technologies, Inc. (OTCQB: EMED) already markets the FDA-cleared WellnessPro Plus(TM) and plans to debut next year the WellnessPlus POD, a smaller, professional, less costly device that features a portal for telemedicine-like real time monitoring by physicians.

The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).

Goldman Small Cap Research Sets A $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED) And Projects The Medical Device Company, Focused On Chronic And Acute Pain Relief, Will Reach Volume Of $1.55 Million In FY2021 And $17 Million In FY2022

Electromedical Technologies, Inc. (OTCQB: EMED) stock is seen by Goldman Small Cap Research as 'grossly undervalued.' The analysis finds, "Even with a 12-month price target of $5.70, EMED's share are grossly undervalued." It also asserts that its volume estimates for 2022 are based on 80,000 units sold in 2022. It notes that the stock could rise by five times its recent price over the next 12 months.

The report, authored by analyst Rob Goldman, said of the company's newest device the WellnessPro POD, "Sales are expected to come from the existing customer base as well as those seeking alternatives to pharmaceuticals such as opioids. Moreover, the new monthly subscription service model should provide valuable recurring revenue to Ekectromedical," Goldman said. Goldman Small Cap Research Sets A $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED) And Projects The Medical Device Company, Focused On Chronic And Acute Pain Relief, Will Reach Volumes Of $1.55 Million In FY2021 And $17 Million In FY2022.

The WellnessPro POD Has A Telemedicine Component

The Company has successfully marketed its non-invasive FDA-cleared WellnessPro Plus(TM) as an alternative treatment to opioid pain killer pharmaceuticals which can be addictive. Electromedical Technologies, Inc. (OTCQB: EMED), then, is an attractive pure play bioelectronics firm with a telemedicine component that should serve as a driver broad product adoption, the report says.

The newest product, the WellnessPro POD, links doctors and patients, and is less costly, smaller, portable, feature-intensive and offers a remote POD portal, enabling physicians real-time monitoring of treatments. It also offers a unique financial sales structure, combining down payment purchase with a prescription, plus a monthly subscription services fee.

Goldman added in the report that stock shares of Electromedical Technologies, Inc. (OTCQB: EMED) "appear very undervalued" when compared with its peer group. "Still, our 12-month price target reflects a reasonable price/revenue multiple, which reflects a big discount to nearly all of its publicly-traded peers. If the Company achieves our projected growth trajectory it it could be afforded a substantially greater valuation," he concluded. Goldman Small Cap Research Sets A $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED) And Projects The Medical Device Company, Focused On Chronic And Acute Pain Relief, Will Reach Volumes Of $1.55 Million In FY2021 And $17 Million In FY2022.

Non-Invasive Devices From Electromedical Technologies, Inc. (OTCQB: EMED) Offer Electrotherapy and Bioelectronic treatments To Ease Chronic And Acute Lower Back, Leg Pain

Electromedical Technologies, Inc. (OTCQB: EMED) Offers Chronic And Acute Pain Relief Through its Devices: the FDA-cleared WellnessPro Plus(TM) and anticipated for late 2021 the new WellnessPro(R) Pod. Electromedical Technologies, Inc. (OTCQB: EMED) has developed devices such as the FDA-cleared WellnessPro Plus(TM) and WellnessPro(R) Pod, expected to be marketed in late 2021 with FDA clearance.

These are non-invasive devices which avoid side-effects such as opioid addiction. They deliver to sufferers of chronic and acute pain relief through electrotherapy and bioelectronic non-invasive treatments. The POD is less costly, smaller, mobile and has a telemedicine portal feature that enables doctors to monitor its treatments in real-time. Goldman Small Cap Research Sets A $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED) And Projects The Medical Device Company, Focused On Chronic And Acute Pain Relief, Will Reach Volumes Of $1.55 Million In FY2021 And $17 Million In FY2022.

Source: Stock Market Press

Join Stock Market Press' newsletter for the latest in IPO, market commentary and company profiles.

Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.

Contact:

Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:

Statements in this news release may be "forward-looking statements." Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

See Stock Market Press disclaimer: http://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press

comtex tracking

COMTEX_374630159/2718/2020-11-18T08:16:41

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.